SCHEMBL109822

SCHEMBL109822

CC(C)(C)OC(=O)NNC(=O)c1ccno1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 6/20 0.48
GFER P55789 3/20 0.48
TDP1 Q9NUW8 1/20 0.47
LMNA P02545 2/20 0.45
ALDH1A1 P00352 2/20 0.45
MAPT P10636 2/20 0.45
KMT2A Q03164 6/20 0.44
MEN1 O00255 4/20 0.42
MAPK1 P28482 1/20 0.42
APLNR P35414 1/20 0.41
POLB P06746 2/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
CSF1R P07333 1/20 0.39
CYP17A1 P05093 1/20 0.37
ACE2 Q9BYF1 1/20 0.37
ESR1 P03372 1/20 0.37
ESR2 Q92731 1/20 0.37
HSD17B10 Q99714 1/20 0.37
RXFP2 Q8WXD0 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6815222 0.81 NAMPT (0.53) GAAGFERLMNAALDH1A1MAPT
SCHEMBL27814361 0.77 KMT2A (0.41) GAAGFERTDP1LMNAALDH1A1
SCHEMBL13701667 0.74 KMT2A (0.51) GAAGFERTDP1LMNAALDH1A1
SCHEMBL7058186 0.74 APLNR (0.39) GAALMNAKMT2AMEN1APLNR
SCHEMBL24671067 0.73 POLB (0.53) GAALMNAALDH1A1MAPTKMT2A
SCHEMBL6624469 0.73 GAA (0.40) GAALMNAALDH1A1KMT2AMEN1
SCHEMBL353475 0.71
SCHEMBL1106944 0.70 KMT2A (0.51) GAAGFERTDP1LMNAALDH1A1
SCHEMBL13527463 0.70 KMT2A (0.51) GAAGFERTDP1LMNAALDH1A1
SCHEMBL2107820 0.70 GAA (0.51) GAATDP1ALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2424869-B1 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS GLAXO GROUP LTD (GB) 2016-06-22 EP disclosed
US-8501946-B2 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine derivatives as P2X7 modulators GLAXO GROUP LIMITED (GB) 2013-08-06 US disclosed
US-8501946-B2 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine derivatives as P2X7 modulators GLAXO GROUP LIMITED (GB) 2013-08-06 US disclosed
US-20120157436-A1 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS GLAXO GROUP LIMITED (GB) 2012-06-21 US disclosed
EP-2424869-A1 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS Glaxo Group Limited (GB) 2012-03-07 EP disclosed
WO-2010125102-A1 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS GLAXO GROUP LIMITED (GB) 2010-11-04 WO disclosed
WO-2010125102-A1 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS GLAXO GROUP LIMITED (GB) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157436-A1 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS P2RX7, P2RX6, P2RX3 GAA 4675/4885GFER 1207/4885TDP1 2029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.